Ziopharm Oncology Inc. (ZIOP) Downgraded to Hold at Zacks Investment Research
According to Zacks, “ZIOPHARM Oncology, Inc. is a biopharmaceutical company engaged in the development and commercialization of a diverse, risk-sensitive portfolio of in-licensed cancer drugs to address unmet medical needs. The Company applies new insights from molecular and cancer biology to understand the efficacy and safety limitations of approved and developmental cancer therapies and identifies proprietary and related molecules for better patient treatment. “
ZIOP has been the topic of a number of other research reports. Mizuho reaffirmed a neutral rating and set a $5.00 target price (down previously from $7.00) on shares of Ziopharm Oncology in a report on Monday, July 18th. Wells Fargo & Co. raised shares of Ziopharm Oncology from an underperform rating to a market perform rating in a report on Wednesday, August 10th. Finally, Griffin Securities reaffirmed a buy rating and set a $21.00 target price on shares of Ziopharm Oncology in a report on Friday, July 1st. Five research analysts have rated the stock with a hold rating, one has issued a buy rating and one has given a strong buy rating to the company. The stock has an average rating of Hold and a consensus price target of $9.75.
Ziopharm Oncology (NASDAQ:ZIOP) opened at 4.88 on Wednesday. The company’s market cap is $636.82 million. The stock’s 50 day moving average is $5.42 and its 200 day moving average is $6.24. Ziopharm Oncology has a 1-year low of $4.45 and a 1-year high of $14.93.
Ziopharm Oncology (NASDAQ:ZIOP) last posted its quarterly earnings results on Tuesday, August 9th. The biotechnology company reported ($1.01) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by $0.90. Ziopharm Oncology had a negative net margin of 2,292.26% and a negative return on equity of 100.01%. The business earned $1.70 million during the quarter, compared to the consensus estimate of $1.52 million. During the same period last year, the firm earned ($0.11) EPS. The business’s revenue for the quarter was up 525.0% on a year-over-year basis. Equities analysts anticipate that Ziopharm Oncology will post ($1.34) earnings per share for the current fiscal year.
A number of institutional investors have recently added to or reduced their stakes in the company. Commonwealth Equity Services Inc boosted its stake in shares of Ziopharm Oncology by 4.7% in the first quarter. Commonwealth Equity Services Inc now owns 46,575 shares of the biotechnology company’s stock worth $346,000 after buying an additional 2,109 shares during the period. Pacad Investment Ltd. acquired a new stake in shares of Ziopharm Oncology during the first quarter worth about $138,000. TIAA CREF Investment Management LLC boosted its stake in shares of Ziopharm Oncology by 4.5% in the first quarter. TIAA CREF Investment Management LLC now owns 447,313 shares of the biotechnology company’s stock worth $3,319,000 after buying an additional 19,211 shares during the period. BlackRock Institutional Trust Company N.A. boosted its stake in shares of Ziopharm Oncology by 0.6% in the first quarter. BlackRock Institutional Trust Company N.A. now owns 3,045,989 shares of the biotechnology company’s stock worth $22,601,000 after buying an additional 17,982 shares during the period. Finally, National Planning Corp boosted its stake in shares of Ziopharm Oncology by 23.7% in the first quarter. National Planning Corp now owns 23,969 shares of the biotechnology company’s stock worth $168,000 after buying an additional 4,600 shares during the period. 44.91% of the stock is owned by institutional investors and hedge funds.
About Ziopharm Oncology
ZIOPHARM Oncology, Inc is a biopharmaceutical company. The Company is seeking to acquire, develop and commercialize, on its own or with partners, a portfolio of cancer therapies through synthetic immuno-oncology. Its clinical-stage product candidate, Ad-RTS-IL-12, is used with the oral activator veledimex.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Ziopharm Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ziopharm Oncology Inc. and related companies with MarketBeat.com's FREE daily email newsletter.